Transforming clinical trials: why Moderna chose the UK for a billion-pound research and development program

A message from our partner [New Scientist logo] [ UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency logo] Every now and then, New Scientist helps a carefully selected commercial partner speak to our audience. Their support helps us produce the high quality journalism we bring you every week. We hope you find today's message relevant and useful.   [The UK's Clinical Trials Transformation. Links to podcast]( Transforming clinical trials: Episode 3 As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program. [Listen now]( Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency.   [Facebook]( [Twitter]( [Instagram]( [LinkedIn]( [TikTok]( [Update preferences]( | [Help]( | [Contact us]( [View in browser]( This email has been sent to {EMAIL}. [Unsubscribe]( from further emails relating to selected third party partners from New Scientist. Do not reply directly to this email. If you have an enquiry, please contact us using the relevant contact details [listed here](. Copyright © New Scientist Ltd Registered Office: Northcliffe House, 2 Derry Street, London, W8 5TT Registered in England. No.10644366 Australian mailing address: PO Box 2315, Strawberry Hills, NSW 2012, Australia Registered in Australia. ABN 22 621 413 170 [Privacy Policy]( | [Terms & Conditions](